The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gastroesophageal Reflux Drugs Market Research Report 2024
Synopsis
Gastroesophageal Reflux Disease (GERD) is a digestive disorder that occurs when acidic stomach juices, or food and fluids back up from the stomach into the esophagus.GERD affects people of all ages—from infants to older adults. People with asthma are at higher risk of developing GERD.
The global Gastroesophageal Reflux Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastroesophageal Reflux Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroesophageal Reflux Drugs.
Report Scope
The Gastroesophageal Reflux Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastroesophageal Reflux Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastroesophageal Reflux Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Cadila Pharmaceuticals
AstraZeneca
Jiangsu Aosaikang
Eisai
Pfizer
Altana Pharma
Takeda
NCPC
Luoxin
Segment by Type
Esomeprazole
Lansoprazole
Omeprazole
Rbeprazole
Dexlansoprazole
Others
Segment by Application
Hospitals
Ambulatory surgical centers
Specialty clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gastroesophageal Reflux Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gastroesophageal Reflux Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Gastroesophageal Reflux Disease (GERD) is a digestive disorder that occurs when acidic stomach juices, or food and fluids back up from the stomach into the esophagus.GERD affects people of all ages—from infants to older adults. People with asthma are at higher risk of developing GERD.
The global Gastroesophageal Reflux Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastroesophageal Reflux Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroesophageal Reflux Drugs.
Report Scope
The Gastroesophageal Reflux Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastroesophageal Reflux Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastroesophageal Reflux Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Cadila Pharmaceuticals
AstraZeneca
Jiangsu Aosaikang
Eisai
Pfizer
Altana Pharma
Takeda
NCPC
Luoxin
Segment by Type
Esomeprazole
Lansoprazole
Omeprazole
Rbeprazole
Dexlansoprazole
Others
Segment by Application
Hospitals
Ambulatory surgical centers
Specialty clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gastroesophageal Reflux Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gastroesophageal Reflux Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Gastroesophageal Reflux Drugs Market Overview
1.1 Product Overview and Scope of Gastroesophageal Reflux Drugs
1.2 Gastroesophageal Reflux Drugs Segment by Type
1.2.1 Global Gastroesophageal Reflux Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Esomeprazole
1.2.3 Lansoprazole
1.2.4 Omeprazole
1.2.5 Rbeprazole
1.2.6 Dexlansoprazole
1.2.7 Others
1.3 Gastroesophageal Reflux Drugs Segment by Application
1.3.1 Global Gastroesophageal Reflux Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Ambulatory surgical centers
1.3.4 Specialty clinics
1.3.5 Others
1.4 Global Gastroesophageal Reflux Drugs Market Size Estimates and Forecasts
1.4.1 Global Gastroesophageal Reflux Drugs Revenue 2019-2030
1.4.2 Global Gastroesophageal Reflux Drugs Sales 2019-2030
1.4.3 Global Gastroesophageal Reflux Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Gastroesophageal Reflux Drugs Market Competition by Manufacturers
2.1 Global Gastroesophageal Reflux Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Gastroesophageal Reflux Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Gastroesophageal Reflux Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Gastroesophageal Reflux Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Gastroesophageal Reflux Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gastroesophageal Reflux Drugs, Product Type & Application
2.7 Gastroesophageal Reflux Drugs Market Competitive Situation and Trends
2.7.1 Gastroesophageal Reflux Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gastroesophageal Reflux Drugs Players Market Share by Revenue
2.7.3 Global Gastroesophageal Reflux Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gastroesophageal Reflux Drugs Retrospective Market Scenario by Region
3.1 Global Gastroesophageal Reflux Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Gastroesophageal Reflux Drugs Global Gastroesophageal Reflux Drugs Sales by Region: 2019-2030
3.2.1 Global Gastroesophageal Reflux Drugs Sales by Region: 2019-2024
3.2.2 Global Gastroesophageal Reflux Drugs Sales by Region: 2025-2030
3.3 Global Gastroesophageal Reflux Drugs Global Gastroesophageal Reflux Drugs Revenue by Region: 2019-2030
3.3.1 Global Gastroesophageal Reflux Drugs Revenue by Region: 2019-2024
3.3.2 Global Gastroesophageal Reflux Drugs Revenue by Region: 2025-2030
3.4 North America Gastroesophageal Reflux Drugs Market Facts & Figures by Country
3.4.1 North America Gastroesophageal Reflux Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Gastroesophageal Reflux Drugs Sales by Country (2019-2030)
3.4.3 North America Gastroesophageal Reflux Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Gastroesophageal Reflux Drugs Market Facts & Figures by Country
3.5.1 Europe Gastroesophageal Reflux Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Gastroesophageal Reflux Drugs Sales by Country (2019-2030)
3.5.3 Europe Gastroesophageal Reflux Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gastroesophageal Reflux Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Gastroesophageal Reflux Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Gastroesophageal Reflux Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Gastroesophageal Reflux Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Gastroesophageal Reflux Drugs Market Facts & Figures by Country
3.7.1 Latin America Gastroesophageal Reflux Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Gastroesophageal Reflux Drugs Sales by Country (2019-2030)
3.7.3 Latin America Gastroesophageal Reflux Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Gastroesophageal Reflux Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Gastroesophageal Reflux Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Gastroesophageal Reflux Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Gastroesophageal Reflux Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gastroesophageal Reflux Drugs Sales by Type (2019-2030)
4.1.1 Global Gastroesophageal Reflux Drugs Sales by Type (2019-2024)
4.1.2 Global Gastroesophageal Reflux Drugs Sales by Type (2025-2030)
4.1.3 Global Gastroesophageal Reflux Drugs Sales Market Share by Type (2019-2030)
4.2 Global Gastroesophageal Reflux Drugs Revenue by Type (2019-2030)
4.2.1 Global Gastroesophageal Reflux Drugs Revenue by Type (2019-2024)
4.2.2 Global Gastroesophageal Reflux Drugs Revenue by Type (2025-2030)
4.2.3 Global Gastroesophageal Reflux Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Gastroesophageal Reflux Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Gastroesophageal Reflux Drugs Sales by Application (2019-2030)
5.1.1 Global Gastroesophageal Reflux Drugs Sales by Application (2019-2024)
5.1.2 Global Gastroesophageal Reflux Drugs Sales by Application (2025-2030)
5.1.3 Global Gastroesophageal Reflux Drugs Sales Market Share by Application (2019-2030)
5.2 Global Gastroesophageal Reflux Drugs Revenue by Application (2019-2030)
5.2.1 Global Gastroesophageal Reflux Drugs Revenue by Application (2019-2024)
5.2.2 Global Gastroesophageal Reflux Drugs Revenue by Application (2025-2030)
5.2.3 Global Gastroesophageal Reflux Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Gastroesophageal Reflux Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Gastroesophageal Reflux Drugs Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Cadila Pharmaceuticals
6.2.1 Cadila Pharmaceuticals Corporation Information
6.2.2 Cadila Pharmaceuticals Description and Business Overview
6.2.3 Cadila Pharmaceuticals Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Cadila Pharmaceuticals Gastroesophageal Reflux Drugs Product Portfolio
6.2.5 Cadila Pharmaceuticals Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca Gastroesophageal Reflux Drugs Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Jiangsu Aosaikang
6.4.1 Jiangsu Aosaikang Corporation Information
6.4.2 Jiangsu Aosaikang Description and Business Overview
6.4.3 Jiangsu Aosaikang Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Jiangsu Aosaikang Gastroesophageal Reflux Drugs Product Portfolio
6.4.5 Jiangsu Aosaikang Recent Developments/Updates
6.5 Eisai
6.5.1 Eisai Corporation Information
6.5.2 Eisai Description and Business Overview
6.5.3 Eisai Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Eisai Gastroesophageal Reflux Drugs Product Portfolio
6.5.5 Eisai Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pfizer Gastroesophageal Reflux Drugs Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Altana Pharma
6.6.1 Altana Pharma Corporation Information
6.6.2 Altana Pharma Description and Business Overview
6.6.3 Altana Pharma Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Altana Pharma Gastroesophageal Reflux Drugs Product Portfolio
6.7.5 Altana Pharma Recent Developments/Updates
6.8 Takeda
6.8.1 Takeda Corporation Information
6.8.2 Takeda Description and Business Overview
6.8.3 Takeda Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Takeda Gastroesophageal Reflux Drugs Product Portfolio
6.8.5 Takeda Recent Developments/Updates
6.9 NCPC
6.9.1 NCPC Corporation Information
6.9.2 NCPC Description and Business Overview
6.9.3 NCPC Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 NCPC Gastroesophageal Reflux Drugs Product Portfolio
6.9.5 NCPC Recent Developments/Updates
6.10 Luoxin
6.10.1 Luoxin Corporation Information
6.10.2 Luoxin Description and Business Overview
6.10.3 Luoxin Gastroesophageal Reflux Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Luoxin Gastroesophageal Reflux Drugs Product Portfolio
6.10.5 Luoxin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gastroesophageal Reflux Drugs Industry Chain Analysis
7.2 Gastroesophageal Reflux Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gastroesophageal Reflux Drugs Production Mode & Process
7.4 Gastroesophageal Reflux Drugs Sales and Marketing
7.4.1 Gastroesophageal Reflux Drugs Sales Channels
7.4.2 Gastroesophageal Reflux Drugs Distributors
7.5 Gastroesophageal Reflux Drugs Customers
8 Gastroesophageal Reflux Drugs Market Dynamics
8.1 Gastroesophageal Reflux Drugs Industry Trends
8.2 Gastroesophageal Reflux Drugs Market Drivers
8.3 Gastroesophageal Reflux Drugs Market Challenges
8.4 Gastroesophageal Reflux Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
